These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9170145)

  • 1. Tryptamine: a possible endogenous substrate for CYP2D6.
    Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
    Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.
    Yu AM; Granvil CP; Haining RL; Krausz KW; Corchero J; Küpfer A; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2003 Feb; 304(2):539-46. PubMed ID: 12538805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine.
    Agúndez JA; Gallardo L; Martínez C; Gervasini G; Benítez J
    Pharmacogenetics; 1998 Jun; 8(3):251-8. PubMed ID: 9682270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
    Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
    Yu AM; Idle JR; Herraiz T; Küpfer A; Gonzalez FJ
    Pharmacogenetics; 2003 Jun; 13(6):307-19. PubMed ID: 12777961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
    Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
    Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium ozagrel on the activity of rat CYP2D6.
    Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
    Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
    Subehan ; Usia T; Kadota S; Tezuka Y
    Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).
    Rodrigues AD; Roberts EM
    Drug Metab Dispos; 1997 May; 25(5):651-5. PubMed ID: 9152607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
    Obach RS; Pablo J; Mash DC
    Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
    Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
    Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
    Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
    Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
    Zhou X; Wang Y; Or PM; Wan DC; Kwan YW; Yeung JH
    Phytomedicine; 2012 May; 19(7):648-57. PubMed ID: 22541637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
    Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
    Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
    Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
    Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.
    Shin JG; Soukhova N; Flockhart DA
    Drug Metab Dispos; 1999 Sep; 27(9):1078-84. PubMed ID: 10460810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.
    Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H
    Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
    Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
    Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
    Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.